RecruitingPhase 1NCT06823167
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies
Sponsor
Immunome, Inc.
Enrollment
117 participants
Start Date
Feb 26, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a biological treatment called IM-1021 for people with hematologic malignancies and solid malignancies. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALIM-1021
IM-1021 is an antibody-drug conjugate
Locations(22)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06823167
Related Trials
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893121 locations
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
NCT072856681 location
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873781 locations
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
NCT075057712 locations
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
NCT057241211 location